U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07151508) titled 'Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab' on Aug. 19.
Brief Summary: In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome.
Study Start Date: Dec. 19, 2023
Study Type: OBSERVATIONAL
Condition:
Neterton Syndrome
Intervention:
DEVICE: Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age
Secukinumab was administered in a weight-adapted dosing regimen equivalen...